Celgene

Suma Kl is the CEO of Celgene.

The decision makers in Celgene are Franz Lechner, James Laforte, Jim Hine, etc. Click to Find Celgene decision makers emails.

Bristol Myers Squibb (BMS) specializes in treating serious diseases, with a strong focus on cancer, hematology, immunology, and inflammation. The company is dedicated to developing innovative therapies for conditions such as various types of cancer, autoimmune diseases, and orphan diseases, ensuring that patients with unmet medical needs have access to effective treatments.

The merger between Celgene and Bristol Myers Squibb has created a leading biopharmaceutical company that enhances the ability to discover, develop, and deliver innovative medicines. This merger combines BMS's expertise in oncology and immunology with Celgene's strengths in hematology and epigenetics, allowing for a broader pipeline of therapies aimed at addressing serious diseases and improving patient outcomes.

Bristol Myers Squibb employs a patient-centric approach to research and development, focusing on innovative science and cutting-edge technologies. The company invests heavily in R&D to discover new therapies, utilizing advanced techniques in translational medicine and protein homeostasis to develop treatments that target the underlying mechanisms of diseases. This commitment to innovation ensures that BMS remains at the forefront of biopharma advancements.

Bristol Myers Squibb is involved in several key therapeutic areas, including oncology, hematology, immunology, and inflammation. The company is particularly known for its work in immuno-oncology, where it develops therapies that harness the body’s immune system to fight cancer. Additionally, BMS addresses orphan diseases, providing targeted treatments for rare conditions that often lack sufficient therapeutic options.

Bristol Myers Squibb is committed to supporting patients and healthcare providers through various initiatives. The company offers patient assistance programs to help eligible individuals access medications, regardless of their financial situation. BMS also provides educational resources and support services for healthcare providers to ensure they have the necessary information to effectively prescribe and manage treatments for their patients.

Innovation is at the core of Bristol Myers Squibb's mission to discover, develop, and deliver transformative medicines. The company prioritizes research that leads to groundbreaking therapies, leveraging advanced technologies and scientific insights to address complex diseases. By fostering a culture of innovation, BMS aims to continuously improve patient outcomes and redefine the standard of care in the biopharmaceutical industry.